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Tavtigian et al., page 427
Homozygous mutations in ATM cause the autosomal-
recessive disorder ataxia-telangiectasia, but for many years
there has been debate over whether heterozygous variants
in ATM increase the risk of developing breast cancer.
Researchers began to suspect that the disease-causing
alleles might have an additional monoallelic effect after
reports of the increased prevalence of breast cancer in the
families of patients with ataxia-telangeictasia. Unfortu-
nately, results of association studies looking for risk vari-
ants have been conﬂicting. Several recent large-scale
studies have added support to the hypothesis that ATM
variants, more speciﬁcally those mutations that cause
ataxia-telangiectasia, do in fact also increase risk of breast
cancer. In this issue, Tavtigian and his colleagues perform
an analysis on several breast cancer data sets to further
delineate the risk conferred by ATM sequence substitu-
tions. By analyzing data from a large number of cases,
the authors are able to identify enough variants so that
they can analyze separately the effects of truncating muta-
tions versus rare missense mutations. Truncating muta-
tions are expected to be deleterious and have an effect,
and that is seen here, but things are more complicated
when the effects of rare missense alleles are assessed. By
using their method of grading each variant on the basis
of its predicted deleterious effect to the gene, the authors
are able to make pools of rare missense alleles. They ﬁnd
evidence that, as the variant is deemed more deleterious,
it is also associated with a larger risk effect. Additional anal-
ysis examines these missense variants in speciﬁc regions of
the gene, and the authors are able to suggest that sequence
substitutions in certain domains have a greater effect than
others.
Clinical Diagnostics in Human Genetics
Kohler et al., page 457
Without the ability to make a proper diagnosis for a sick
patient, clinicians can have signiﬁcant difﬁculty in recom-
mending appropriate treatment, predicting disease prog-
nosis, or providing constructive genetic counseling. Unfor-
tunately, the tremendous number of disease possibilities,
along with the overlap of phenotypes in and the rarity
of many of them, makes it impossible for physicians toalways recognize a disease on the basis of their experience
alone. For aiding in the clinical diagnositic process, pheno-
typic data have been compiled into searchable databases
that allow users to input the features of a patient and
generate a list of possible candidate diagnoses. Although
such lists surely assist clinicians and their patients, Kohler
and colleagues suggest that additional advancements to
the process could improve the utility of the output. Here,
the authors report on their development of a statistical
model implemented in a web application named the Phe-
nomizer that works with the terms included in the human
phenotype ontology to produce a ranked list of candidate
diagnoses and assign each with a signiﬁcance score. If
the phenotypic input is not speciﬁc enough to generate
a list of signiﬁcant differential diagnoses, the physician
then learns that more speciﬁc details about the patient’s
condition need to be collected. This will potentially
contribute to tailored follow-up and specialist recommen-
dations that will focus on distinguishing one group of
syndromes from another.
Familial Hemophagocytic Lymphohistiocytosis
Due to Mutations in STXBP2
zur Stadt et al., page 482
Hemophagocytic lymphohistiocytosis (HLH) is a severe
syndrome in which the immune system is highly dysregu-
lated, resulting in the eventual loss of immune homeo-
stasis. HLH patients are affected by fever, hepatosplenome-
galy, and cytopenia, and the condition is often fatal if
proper immunosuppressive treatment is not administered.
Genetic studies of the familial form of the disorder (FHL)
have identiﬁed mutations in PRF1, UNC13D, and STX11
that are responsible for the disease in a percentage of
inherited cases, but a great deal of genetic heterogeneity
has been observed and a number of cases remain in which
no mutations have been found. In an effort to learn more
about the genes that are dysfunctional in FHL, zur Stadt
and colleagues perform homozygosity mapping in FHL
patients who do not have any mutations in the known
genes. Their inspection of the genes in a locus on 19p
reveals a number of mutations in STXBP2 that encode
the syntaxin binding protein 2. The missense mutations
are shown to affect protein stabilization and also disrupt
the interaction between STXBP2 and STX11. Although
the function of STXBP2 is not yet well understood, its1Deputy Editor, AJHG
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colocalization and relationship with STX11 in hematopoi-
etic cells suggests that the two proteins work together in
the process of granule exocytosis.
IREB2 Variants in Chronic Obstructive Pulmonary
Disease
De Meo et al., page 493
Although genome-wide methods have been successful in
identifying a number of genetic variants associated with
complex disease, the cost of correcting for the large
number of tests involved with evaluating so many markers
can decrease a study’s ability to observe signiﬁcant associ-
ations. Oneway tominimize the need for a large correction
is to limit the number of markers tested by focusing in on
regions or genes that are most likely to be involved in
disease pathogenesis. De Meo and colleagues use such a
strategy here in their research to identify risk alleles for
chronic obstructive pulmonary disease (COPD). A number
of studies have identiﬁed variants with signiﬁcant effects,
but results have not always replicated. Here, the authors
reduce the number of markers they analyze by ﬁrst exam-
ining which genes are differentially expressed in patients
and controls. Their analysis pinpoints a signiﬁcant associ-
ation between variants in IREB2 and the risk of developing
COPD. IREB2 expression is higher in patients than in
controls and the protein localizes to a number of structures
within lung tissue. Of note, IREB2 SNPs have also been
associated with lung cancer risk. The authors suggest that
IREB2’s role in iron metabolism is a factor in COPD devel-
opment on the basis of previous work that suggests a rela-422 The American Journal of Human Genetics 85, 421–422, Octobertionship between the distribution of lung iron and inﬂam-
mation.
Incidence of Fragile X Syndrome
Coffee et al., page 503
Once the trinucleotide repeat expansion in the 50 UTR of
FMR1 surpasses a certain length, it causes Fragile X
syndrome (FXS) via hypermethylation and gene silencing.
Traditionally, researchers determine whether an individual
has such a long repeat expansion, termed a full mutation,
through Southern blot and PCR techniques. These
methods are costly and cumbersome and do not always
yield reliable results, so using them for high-throughput
assessment of a large number of samples has not been a
reasonable possibility. In this issue, Coffee and colleagues
report their development of a FXS-screening method that
capitalizes on the fact that the FMR1 promoter is differen-
tially methylated in those with the full mutation versus
those without. Speciﬁcally, male FXS patients with a full
expansion mutation have a high level of FMR1 methyla-
tion and unaffected males have no methylation. Similarly,
female carriers of a full mutation have a high ratio of meth-
ylated versus unmethylated FMR1. The authors validate
their strategy on a set of male samples and demonstrate
that they are able to detect the full-mutation carriers
with 100% sensitivity and 100% speciﬁcity. With such an
effective and low-cost screening tool, the authors are able
to analyze over 36,000 newborn blood samples to make
an unbiased estimate of the incidence of FXS in the general
population.9, 2009
